Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

RECRUITING

Identifier: CI-TRIAL-00119644
Entity page: /trial/NCT04198766 ↗
Edges: 17

Neighbours: 7 cancers7 drugs
Drawn: 14 of 14 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) condition of …CONDITION_OFderived8 of 8
← condition of	Lung Non-Small Cell Carcinoma registry condition “Resectable Non-Small-Cell Lung Cancer” mapped CURATED_BROADER	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
← condition of	Lung Non-Small Cell Carcinoma registry condition “Non-Small Cell Lung Cancer” mapped ALIAS

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) intervention of …INTERVENTION_OFderived9 of 9
← intervention of	Carboplatinsmall molecule registry intervention “Carboplatin AUC-5” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Carboplatinsmall molecule registry intervention “Carboplatin AUC-6” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cisplatinsmall molecule registry intervention “Cisplatin 75mg/m2” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine (1000 mg/m2)” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Nab-paclitaxel registry intervention “Nab paclitaxel 100mg/m2” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Paclitaxelsmall molecule registry intervention “Paclitaxel 200mg/m2” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “pembrolizumab 200 mg” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “pembrolizumab 400 mg” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pemetrexedsmall molecule registry intervention “Pemetrexed 500 mg/m2” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) intervention of …INTERVENTION_OFderived9 of 9

← intervention of

Carboplatinsmall molecule

registry intervention “Carboplatin AUC-5” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Carboplatinsmall molecule

registry intervention “Carboplatin AUC-6” (DRUG) mapped ALIAS

—